Volume : 10, Issue : 01, January – 2023
Title:
35.A CASE REPORT OF SEVERE HYPERKALEMIA ASSOCIATED WITH COMBINATION THERAPIES FOR CHRONIC HYPERTENSION ALONG WITH OBESITY AND TYPE II DIABETES
Authors :
Noor-ul-Ain*, Laiba Arooj, Sana Saeed
Abstract :
Hyperkalemia associated with the antihypertensives is a leading condition among the hypertensive individuals especially those who are suffering from chronic hypertension and other metabolic disorders like diabetes mellitus and obesity. The combination of therapies of high dose of Hydrochlorothiazde, Valsartan and Amlodipine for last two years given to the patient leads to severe adverse effects some of which are irreversible. In this case a female patient of age 62 years appeared in emergency with severe vomiting, nausea, SOB (shortness of breath), pulmonary edema and arrhythmia. ECG shows prolongation of the PR and QRS intervals, and her laboratory reports were showing increased creatinine, serum urea level and a very high potassium level. She was given symptomatic treatment to treat her symptoms and later on she was undergone hemodialysis to remove the excessive potassium from her body and she got recovered later on.
Key words: Associated, combination, high dose, Irreversible, Excessive.
Cite This Article:
Please cite this article in press Noor-ul-Ain et al, A Case Report Of Severe Hyperkalemia Associated With Combination Therapies For Chronic Hypertension Along With Obesity And Type Ii Diabetes., Indo Am. J. P. Sci, 2023; 10(01).
Number of Downloads : 10
References:
1. Chang, A.R., Sang, Y., Leddy, J., Yahya, T., Kirchner, H.L., Inker, L.A., Matsushita, K., Ballew, S.H., Coresh, J. and Grams, M.E., 2016. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension, 67(6), pp.1181- 1188.
2. Weinberg, J.M., Appel, L.J., Bakris, G., Gassman, J.J., Greene, T., Kendrick, C.A., Wang, X., Lash, J., Lewis, J.A., Pogue, V. and Thornley-Brown, D., 2009. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Archives of internal medicine, 169(17), pp.1587-1594.
3. Zhu, S., Li, J. and Zhao, X., 2021. Comparative risk of new‐onset hyperkalemia for antihypertensive drugs in patients with diabetic nephropathy: A Bayesian network meta‐analysis. International Journal of Clinical Practice, 75(8), p.e13940.
4. Rizk, J.G., Lazo, J.G., Quan, D., Gabardi, S., Rizk, Y., Streja, E., Kovesdy, C.P. and Kalantar-Zadeh, K., 2021. Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients. Reviews in Endocrine and Metabolic Disorders, pp.1-14.
5. Uchida, K., Azukizawa, S., Nakano, S., Kaneko, M., Kigoshi, T., Morimoto, S. and Matsui, A., 1994. Reversible hyperkalemia during antihypertensive therapy in a hypertensive diabetic patient with latent hypoaldosteronism and mild renal failure. Southern medical journal, 87(11), pp.1153-1155.
6. Sasmita, B.R., Luo, S. and Huang, B., 2022. Hyperkalemia mimicking de Winter T waves: A case report. Clinical Case Reports, 10(12), p.e6783.
7. Xie, W., He, S., Hong, G., Xiao, Z., Dong, Y., Xu, X. and Zhang, Y., 2022. Relationship between Rasi and Hyperkalemia in Maintenance Hemodialys Patients.
8. Pierce, C.W., 2022. Reconsidering convention: dietary potassium in at-risk populations with chronic hyperkalemia.